Navigation Links
Arena Pharmaceuticals to Present at the 13th Annual BIO CEO & Investor Conference
Date:2/9/2011

of lorcaserin; the Eisai collaboration and potential activities thereunder; and Arena's focus, goals, strategy, research and development programs, and ability to develop compounds and commercialize drugs. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, the following: the risk that regulatory authorities may not find data and other information related to Arena's clinical trials and other studies meet safety or efficacy requirements or are otherwise sufficient for regulatory approval; the timing of regulatory review and approval is uncertain; Arena's response to the complete response letter for the lorcaserin NDA may not be submitted when anticipated or the information provided in such response may not satisfy the FDA; the FDA may request other information prior to or after Arena resubmits the lorcaserin NDA or approval of the lorcaserin NDA; unexpected or unfavorable new data; risks related to commercializing new products; Arena's ability to obtain and defend its patents; the timing, success and cost of Arena's research and development programs; results of clinical trials and other studies are subject to different interpretations and may not be predictive of future results; clinical trials and other studies may not proceed at the time or in the manner Arena or others expect or at all; Arena's ability to obtain adequate funds; risks related to relying on collaborative agreements; the timing and receipt of payments and fees, if any, from collaborators; and satisfactory resolution of pending and any future litigation or other disagreements with others. Additional factors that could cause actual results to differ materially from those stated or implied by Arena's forward-looking statements are disclosed in Arena'
'/>"/>
SOURCE Arena Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
2. Arena Pharmaceuticals to Present at the Natixis Bleichroeder Second Annual Hidden Gems Conference
3. Arena Pharmaceuticals to Present at the BIOCOM Investor Conference
4. Arena Pharmaceuticals to Report Third Quarter 2008 Financial Results and to Host Conference Call and Webcast on Thursday, October 30, 2008
5. Arena Pharmaceuticals to Present at the Oppenheimer 19th Annual Healthcare Conference
6. Arena Pharmaceuticals to Present at the 27th Annual J.P. Morgan Healthcare Conference
7. Arena Pharmaceuticals Obtains Equity Financing Commitment of Up to $50 Million
8. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Monday, May 11, 2009
9. Arena Pharmaceuticals Announces First Quarter 2009 Financial Results
10. Arena Pharmaceuticals to Present at the 8th Annual Needham Life Sciences Conference
11. Arena Pharmaceuticals to Present at the Rodman & Renshaw Annual Global Investment Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/27/2014)... 27, 2014 The new research ... (High & Medium), Sub-type (Primary & Secondary), and ... & Transportation & Power Generation) - Trends and ... market with analysis and forecasting of the market ... Tables with 52 Figures spread through 146 Pages ...
(Date:10/27/2014)... NEW YORK , Oct. 27, 2014 ... in the recent Ebola concern in the ... for the virus.  The healthcare market researcher said the ... of in vitro diagnostic tests for the detection of ... sensitivity has proved useful.  Kalorama routinely assess the IVD ...
(Date:10/27/2014)... Called the NOAH Protocol, this investigative ... of pediatric brain cancer. The implications for groundbreaking ... years of research and development. Amber Larkin, the ... mom's determination can make a difference. , ... it’s only fitting that we’ve received FDA approval ...
(Date:10/27/2014)... Pa. , Oct. 27, 2014 ... Foundation of America (CCFA) announced today the launch ... , an educational campaign designed to ... diseases (IBD) on the paired role of nutrition ... To view the multimedia assets associated with this ...
Breaking Biology Technology:Gas Insulated Switchgear Market worth $21,951.9 Million by 2019 - New Report by MarketsandMarkets 2Gas Insulated Switchgear Market worth $21,951.9 Million by 2019 - New Report by MarketsandMarkets 3Gas Insulated Switchgear Market worth $21,951.9 Million by 2019 - New Report by MarketsandMarkets 4Kalorama: PCR The Go-to Test in Ebola Fight 2Kalorama: PCR The Go-to Test in Ebola Fight 3FDA Approves Breakthrough in Pediatric Brain Cancer - First in 30 Years 2FDA Approves Breakthrough in Pediatric Brain Cancer - First in 30 Years 3Celebrity Cook Sunny Anderson Teams Up With Janssen And Crohn's & Colitis Foundation Of America To Launch Educational Campaign 2Celebrity Cook Sunny Anderson Teams Up With Janssen And Crohn's & Colitis Foundation Of America To Launch Educational Campaign 3Celebrity Cook Sunny Anderson Teams Up With Janssen And Crohn's & Colitis Foundation Of America To Launch Educational Campaign 4
... 2011 Although top bio-pharmaceutical companies agree that Key ... of a new product, increasing competition has made it ... the role of Medical Science Liaisons (MSLs) in forging ... recent years. In fact, today, ...
... YORK, March 21, 2011 Reportlinker.com announces that ... its catalogue: Global Nanobiotechnology Industry ... This report analyzes the worldwide markets for Nanobiotechnology ... - Nanomaterials (Solid Inorganic Nanoparticles, Nanocomposites, Nanostructured Materials ...
... China PharmaHub Corp. (OTC Bulletin Board: CPHB ... that it has signed a exclusive worldwide license agreement ... develop, commercialize and market a universal donor blood product ... Professor of Medicine and Pediatrics Dr. Ewa Carrier. The ...
Cached Biology Technology:Newly Updated for 2011: Medical Science Liaison Study Shows Growth in KOL Outreach, Impact 2Reportlinker Adds Global Nanobiotechnology Industry 2Reportlinker Adds Global Nanobiotechnology Industry 3Reportlinker Adds Global Nanobiotechnology Industry 4Reportlinker Adds Global Nanobiotechnology Industry 5Reportlinker Adds Global Nanobiotechnology Industry 6Reportlinker Adds Global Nanobiotechnology Industry 7Reportlinker Adds Global Nanobiotechnology Industry 8Reportlinker Adds Global Nanobiotechnology Industry 9Reportlinker Adds Global Nanobiotechnology Industry 10Reportlinker Adds Global Nanobiotechnology Industry 11Reportlinker Adds Global Nanobiotechnology Industry 12Reportlinker Adds Global Nanobiotechnology Industry 13Reportlinker Adds Global Nanobiotechnology Industry 14Reportlinker Adds Global Nanobiotechnology Industry 15Reportlinker Adds Global Nanobiotechnology Industry 16Reportlinker Adds Global Nanobiotechnology Industry 17China PharmaHub In-Licenses Universal Donor Red Blood Cells Technology Exclusively From University of California, San Diego 2
(Date:10/29/2014)... As bodies decompose, their types and numbers of ... provide could mean the difference between a closed ... University is using a more than $866,000 U.S. ... investigators examine these changing populations. The microbial communities ... of death, gender, race, socioeconomic relations and more, ...
(Date:10/29/2014)... — Cambridge, MA and Hebei, China — BGI Tech ... quality sequencing of the Jujube genome. Jujube is the ... the Jujube genome is particularly difficult to sequence due ... It is the first time that a genome in ... has been recently published in Nature Communications ...
(Date:10/29/2014)... kidney cancer patients in Europe sheds light on the ... apparent link between exposure to aristolochic acid and incidence ... by an international team led by scientists from the ... underscores the importance of investigating possible sources of exposure ... the Aristolochia genus, also has been suspected of causing ...
Breaking Biology News(10 mins):MSU partners with Detroit to investigate death scenes 2BGI Tech and Hebei Agricultural University complete the genome sequencing of the jujube tree 2Study sheds light on genetic architecture of kidney cancer 2Study sheds light on genetic architecture of kidney cancer 3
... in Clive Svendsen,s lab dishes, he couldn,t have been ... type lost in patients with the devastating neurological disease ... Wisconsin-Madison stem cell biologist had recreated the hallmarks of ... derived from a patient. By allowing scientists the ...
... genes that control the handedness of snail shells, and they ... humans to set up the left and right sides of ... publication in Nature by University of California, Berkeley, ... establishing the left-right asymmetry of animals for 500-650 million years, ...
... Thirteen UC Riverside researchers have been named fellows of ... Including this years fellows, the total number of UCR ... distinction is 172., Election as a fellow is an ... year AAAS gave this honor to 486 of its ...
Cached Biology News:Patient-derived induced stem cells retain disease traits 2Patient-derived induced stem cells retain disease traits 3Snails and humans use same genes to tell right from left 2Snails and humans use same genes to tell right from left 3Snails and humans use same genes to tell right from left 413 UCR faculty members recognized by American Association for the Advancement of Science 213 UCR faculty members recognized by American Association for the Advancement of Science 3
Chlamydia pneumoniae (TWAR)...
Mouse anti-HIV-Imn PND Class: Antibody Product Group: Bacterial and Viral Antigen...
Mouse monoclonal [CP23] to Ricin communis ( Abpromise for all tested applications)....
... Antibody - Red, 20X ... antibody at 20X concentration for use ... assays. Quality Assurance ... FarRed fluorescence polarization assays. ...
Biology Products: